ODM-209 showed activity in heavily pretreated participants with mCRPC, particularly those with activating AR-LBD mutations, with an expected AE profile.
A. Bernard-Tessier, I. Spanggaard, T. Utriainen et al.· European Journal of Cancer· 0 citations
Abstract The development of liver metastases in prostate cancer is associated with aggressive disease and poor prognosis. Because hepatocytes exhibit high metabolic activity with unique secretory profiles, we hypothesized that hepatocyte-to-tumor cell signaling plays a role in promoting liver metastasis. We evaluated s...
Jacob Egelberg, Rebecca Kim, M. J. Kim et al.· Cancer Research Communicatio...· 0 citations
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION trial demonstrated that [177Lu]Lu-PSMA-617 significantly improves overall survival and radiographic progression-free su...
H. Noamen, A. Bekkhoucha, A. Bernard-Tessier et al.· Frontiers in Medicine· 0 citations
A national questionnaire to assess radiology reports (RR) physicians’ reading habits and identify their expectations towards RR, focusing on CT and MRI reports, prompts consideration of tailoring reporting practices to the profile of the requesting physician.
Yasmine Kassab, Matthieu Bailly, Sixtine Brabant et al.· Insights into Imaging· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.